drugset / Trial / NCT04311710
A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types
Non-randomizedSequentialOpen-labelTreatment
Summary
A study evaluating the drug levels of ipilimumab alone and in combination with nivolumab applied under the skin in various tumor types
Timeline
- Start
- 2020-06-25
- Primary completion
- 2021-01-14
- Completion
- 2023-01-18
Outcome
Outcome not reported
Stopped (Business): “Business objectives have changed”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | — | Subcutaneous |
| Subject | Nivolumab | Monoclonal antibody | — | Subcutaneous |
| Background | rHuPH20 | Protein / enzyme biologic | — | — |